Molecular Profile |
Indication/Tumor Type |
Response Type |
Relevant Treatment Approaches |
Therapy Name |
Approval Status |
Evidence Type |
Efficacy Evidence |
References |
MET wild-type
|
colorectal cancer
|
decreased response |
|
Glesatinib
|
Preclinical - Cell line xenograft |
Actionable |
In a preclinical study, Glesatinib (MGCD265) treatment resulted in only partial growth inhibition in cell line xenograft models of MET wild-type colorectal cancer (PMID: 28765324).
|
28765324
|
MET wild-type
|
prostate cancer
|
decreased response |
|
Glesatinib
|
Preclinical - Cell line xenograft |
Actionable |
In a preclinical study, Glesatinib (MGCD265) treatment resulted in only partial growth inhibition in cell line xenograft models of MET wild-type prostate caner (PMID: 28765324).
|
28765324
|
MET wild-type
|
cholangiocarcinoma
|
sensitive |
|
Merestinib
|
Preclinical - Pdx & cell culture |
Actionable |
In a preclinical study, LY2801653 inhibited phosphorylation of Met, resulting in inhibition of cholangiocarcinoma proliferation in cell culture and growth of tumors in Pdx models (PMID: 26757360).
|
26757360
|
MET wild-type
|
bladder carcinoma
|
decreased response |
|
Glesatinib
|
Preclinical - Cell line xenograft |
Actionable |
In a preclinical study, Glesatinib (MGCD265) treatment resulted in only partial growth inhibition in cell line xenograft models of MET wild-type urinary bladder carcinoma (PMID: 28765324).
|
28765324
|
MET wild-type
|
prostate cancer
|
sensitive |
|
BMS-777607
|
Preclinical |
Actionable |
In a preclinical study, BMS-777607 (ASLAN002) demonstrated efficacy in inhibiting migration and invasion of cultured prostate cancer cells expressing wild-type Met (PMID: 20515943).
|
20515943
|
MET wild-type
|
Advanced Solid Tumor
|
decreased response |
|
Glesatinib
|
Preclinical - Cell line xenograft |
Actionable |
In a preclinical study, Glesatinib (MGCD265) treatment resulted in only partial growth inhibition in MET wild-type cell line xenograft models of various tumor types (PMID: 28765324).
|
28765324
|
MET wild-type
|
pancreatic cancer
|
decreased response |
|
Glesatinib
|
Preclinical - Cell line xenograft |
Actionable |
In a preclinical study, Glesatinib (MGCD265) treatment resulted in only partial growth inhibition in cell line xenograft models of MET wild-type pancreatic cancer (PMID: 28765324).
|
28765324
|
MET wild-type
|
breast cancer
|
decreased response |
|
Glesatinib
|
Preclinical - Cell line xenograft |
Actionable |
In a preclinical study, Glesatinib (MGCD265) treatment only resulted in partial growth inhibition in cell line xenograft models of MET wild-type breast cancer (PMID: 28765324).
|
28765324
|